Die Resistenz des Mycobacterium tuberculosis gegen Ethionamid, Thiosemicarbazon und Isoxyl und ihre Beziehungen zueinander

  • H. Eule
  • E. Werner
Article

Zusammenfassung

An Stämmen von 522 Lungentuberkulösen wurde in 1596 Testungen die Empfindlichkeit gegen Isoxyl, Thiosemicarbazon und Ethionamid gleichzeitig geprüft. In diesem Routinematerial betrug die Häufigkeit einer Thiosemicarbazonresistenz 8,2%, der Isoxylresistenz 10,1% und der Ethionamidresistenz 6,5%. Die Kreuzresistenz zwischen Thiosemicarbazon und Ethionamid ist sehr häufig. In 75% war die Isoxylresistenz mit einer Thiosemicarbazonresistenz gekoppelt. Eine primäre Resistenz gegen Isoxyl wurde in 3,5%, eine primäre Thiosemicarbazonresistenz in 1,5% beobachtet. Von den isoxylresistenten Stämmen waren 52,8% auch gegen Thiosemicarbazon und Ethionamid, weitere 22,6% nur gegen Thiosemicarbazon resistent. Eine Kreuzresistenz zwischen Isoxyl und Ethionamid wurde nur dann gefunden, wenn gleichzeitig auch eine Thiosemicarbazonresistenz bestand. Eine durch Isoxylbehandlung ausgelöste Isoxylresistenz kann von einer Thiosemicarbazonkreuzresistenz begleitet sein. Sie scheint jedoch nicht eine gekreuzte Ethionamidresistenz im Gefolge zu haben. Die Bedeutung dieser Feststellungen für die klinische und ambulante Chemotherapie wird erörtert.

Resistance of mycobacterium tuberculosis to ethionamide, thiacetazone and isoxyl and their relations to each other

Summary

In simultaneous examinations of sensitivity to Isoxyl, Thiacetazone and Ethionamide in 1596 samples of strains of 522 tuberculous patients we found a frequency of resistance to Thiacetazone in 8,2%, to Isoxyl in 10,1% and to Ethionamide in 6,5% of samples. Cross resistance between Thiacetazone and Ethionamide occurs frequently. In 75% the resistance to Isoxyl was connected with someone to Thiacetazone. Primary resistance to Isoxyl was seen in 3,5%, to Thiacetazone in 1,5%. 52,8% of the strains resistant to Isoxyl were also resistant to Thiacetazone and Ethionamide, 22,6% only to Thiacetazone. Cross resistance between Isoxyl and Ethionamide was found only in cases presenting simultaneous resistance to Thiacetazone. Resistance to Isoxyl produced by treatment with Isoxyl may be accompanied by Thiacetazone resistance. However, a crossed resistance to Ethionamide does not succeed apparently.

The importance of this statement for clinical and ambulant chemotherapy is discussed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Bignall, J. R.: „Isoxyl“, Leading article. Tubercle (Lond.)46, 298 (1965).PubMedGoogle Scholar
  2. [2]
    Böszörmenyi, M.: Controlled clinical study of the therapeutic effect of various combinations, including that of INH with Thiosemicarbazone. International Congress Series No.63, 330–331. Excerpta Medica Foundation Amsterdam (1963).Google Scholar
  3. [3]
    Chicou, F.: Methods of chemotherapy in developing countries. International Congress Series No.96, 36–37. Excerpta Medica Foundation Amsterdam (1965).Google Scholar
  4. [4]
    Compte rendu de la Commission du Traitement. Bull. Un. int. Tuberc.36, 56 (1965).Google Scholar
  5. [5]
    Cooperative study unit on chemotherapy of tuberculosis of the National Sanatoria in Japan: Comparison of PAS, Thiacetazone or 4-4′Diisoamyloxythiocarbanilide with Streptomycine and Isoniazid in previously untreated patients with pulmonary tuberculosis. Tubercle (Lond.)46, 178 (1965).Google Scholar
  6. [6]
    East African/British Medical Research Council. Second Thiacetazone Investigation. Tubercle (Lond.)44, 301 (1963).Google Scholar
  7. [7]
    East African/British Medical Research Council. Thiacetazone/Diphenylthiourea Investigation. Tubercle (Lond.)41, 399 (1960).Google Scholar
  8. [8]
    Eule, H.: Ethionamid- und Thiosemikarbazon-Kreuzresistenz und ihre Bedeutung für die Klinik. Z. Tuberk.123, 36 (1965).PubMedGoogle Scholar
  9. [9]
    ——, u.E. Werner: Thiocarlide (4′4-Diisoamyloxythiocarbanilide) blood levels in patients suffering from tuberculosis. Tubercle (Lond.)47, 214 (1966).PubMedGoogle Scholar
  10. [10]
    Favez, G.: Essai thérapeutique du 4-4′Diisoamyloxythiocarbanilide en tuberculose pulmonaire. Schweiz. Z. Tuberk.18, 379 (1961).PubMedGoogle Scholar
  11. [11]
    ——, andP. Bréaud: Protection from resistance to INH by the combination of INH-isoxyl in the treatment of open pulmonary tuberculosis. International Congress Series No.63, 306–307. Excerpta Medica Foundation Amsterdam (1963).Google Scholar
  12. [12]
    Lees, A. W.: Ethionamide and Isoniazid in previously untreated cases of pulmonary tuberculosis. International Congress Series No.96, 112–113. Excerpta Medica Foundation Amsterdam (1965).Google Scholar
  13. [13]
    Meissner, G.: Häufigkeit der Resistenz für Conteben und deren Bedeutung für das Auftreten der Resistenz für Isoxyl (4-4′Diisoamyloxythiocarbanilid) bei Tuberkelbakterien. Prax. Pneumol.19, 387 (1965).PubMedGoogle Scholar
  14. [14]
    ——, u.D. Stottmeier: Die Empfindlichkeit der Mycobakterien für 4-4′Diisoamyloxythiocarbanilid (Isoxyl) und ihre Bestimmung auf Löwenstein-Jensen-Nährboden. Beitr. Klin. Tuberk.130, 289 (1965).Google Scholar
  15. [15]
    Mitchison, D. A., andJ. Lloyd: Comparison of the sensitivity to Thiacetazone of tubercle bacilli from patients in Britain, East Africa, South India and Hong Kong. Tubercle (Lond.)45, 360 (1964).PubMedGoogle Scholar
  16. [16]
    Moodie, A. S., S. M. Aquinas, andR. D. Foord: Controlled clinical trial of 4-4′Diisoamyloxythiocarbanilide in the treatment of pulmonary tuberculosis. Tubercle (Lond.)45, 192 (1964).PubMedGoogle Scholar
  17. [17]
    Olejnicek, M., M. Weberová, M. Novak, andE. Jancik: A controlled trial of Isoniazid and 4-4′Diisoamyloxythiocarbanilide compared with Isoniazid and PAS and Isoniazid, Streptomycin and PAS. Tubercle (Lond.)46, 188 (1965).PubMedGoogle Scholar
  18. [18]
    Radenbach, K. L.: Therapeutic possibilities of minor antibacterial drugs against infections with Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 1065–1073 (1965). Copyright 1966 American Society for Microbiology.Google Scholar
  19. [19]
    Research Committee of the British Tuberculosis Association and the Tuberculosis Treatment Services in Hong Kong. A controlled trial of Ethionamide with Isoniazid in the treatment of pulmonary tuberculosis in Hong Kong. Tubercle (Lond.)45, 299 (1964).Google Scholar
  20. [20]
    Urbancik, B.: A clinical trial of thiocarlide (4-4′Diisoamyloxythiocarbanilide). Tubercle (Lond.)47, 283 (1966).PubMedGoogle Scholar
  21. [21]
    Urbancik, R., andL. Trnka: Report on the antimicrobial activity of Isoxyl on M. tuberculosis „in vitro“ and „in vivo“. Acta tuberc. pneumol. belg.54, 66 (1963).PubMedGoogle Scholar
  22. [22]
    Verbist, L.: Susceptibility of Mycobacteria to 4-4′Diisoamyloxythiocarbanilide. Antimicrobial Agents and Chemotherapy 298–305 (1965). Copyright 1966 American Society for Microbiology.Google Scholar
  23. [23]
    WHO Expert Commitee on Tuberculosis. Wld Hlth Org. techn. Rep. Ser. (Geneva)290, 1–24 (1964).Google Scholar

Copyright information

© Springer-Verlag 1967

Authors and Affiliations

  • H. Eule
    • 1
  • E. Werner
    • 1
  1. 1.Klinik für Tuberkulose und Lungenkrankheiten des Magistrats von Groß-Berlin, Abt. Gesundheits- und SozialwesenHellmuth-Ulrici-KlinikSommerfeld

Personalised recommendations